Quell Therepeutics
PITCH
At Quell we seek to deliver truly innovative, life-changing therapies for our patients. Our vision as a company is to build a major global biopharmaceutical company bringing transformational and valued therapies for a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation, based on modular engineered Tregs.
LATEST INVESTMENT
£117M
Fidelity, Tekla Capital Management, Point72 Ventures, SV Health Investors, Future Fund, Janus Henderson Investors, Breakthrough Energy Ventures, Ridgeback Capital, British Patient Capital (BPC), Syncona, Monashee Investment Management & Jeito Capital
£60.4M
Syncona Ltd & UCL Technology Fund